Safety and Efficacy of Intrathecal Rituximab in Patients With Lymphoid Malignancies Involving the Central Nervous System
Phase of Trial: Phase I/II
Latest Information Update: 26 May 2018
At a glance
- Drugs Rituximab (Primary)
- Indications Lymphoid leukaemia
- Focus Therapeutic Use
- 28 Mar 2017 Status changed from active, no longer recruiting to discontinued.
- 05 Oct 2016 Status changed from recruiting to active, no longer recruiting.
- 27 May 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.